Effects of carbapenems and their combination with amikacin on murine gut colonisation by Candida albicans

Mycoses

Volumn 56, Issue 2, 2013, Pages 105-109

  Samonis, George ^a   Galanakis, Emmanouil ^a   Ntaoukakis, Markos ^b   Sarchianaki, Emmanouela ^b   Spathopoulou, Thomai ^b   Dimopoulou, Dimitra ^a   Kofteridis, Diamantis P ^a   Maraki, Sofia ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Amikacin; Candida albicans; Carbapenems; Gastrointestinal tract; Mice

Indexed keywords

AMIKACIN; CILASTATIN PLUS IMIPENEM; DORIPENEM; ERTAPENEM; MEROPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FECES CULTURE; FUNGAL COLONIZATION; GASTROINTESTINAL TRACT; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CARBAPENEMS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GASTROINTESTINAL TRACT; HUMANS; MALE; MICE;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; MURINAE; MUS;

EID: 84874337683     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02212.x     Document Type: Article

References (28)

1. Castón-Osorio JJ, Rivero A, Torre-Cisneros J. Epidemiology of invasive fungal infection. Int J Antimicrob Agents 2008; 32(Suppl. 2): 103-9.
2. Person AK, Kontoyiannis DP, Alexander BD. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 2010; 24: 439-59.
3. Shoham S, Marwaha S. Invasive fungal infections in the ICU. J Intensive Care Med 2010; 25: 78-92.
4. Rüping MJ, Vehreschild JJ, Cornely OA. Patients at risk of invasive fungal infections: when and how to treat. Drugs 2008; 68: 1941-62.
5. Muskett H, Shahin J, Eyres G et al. Risk factors for invasive fungal disease in critically ill, adult patients: a systematic review. Crit Care 2011; 15: R287.
6. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
7. Chang A, Neophytos D, Horn D. Candidemia in the 21th century. Future Microbiol 2008; 3: 463-72.
8. Morgan J, Meltzer MI, Plicaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
9. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia; a systemic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-25.
10. Kennedy MJ, Volz PA. Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia 1985; 23: 265-73.
11. Kennedy MJ, Volz PA, Edward CA, Yancey RJ. Mechanisms of association of Candida albicans with intestinal mucosa. J Med Microbiol 1987; 24: 333-41.
12. Krause W, Matheis H, Wulf K. Fungemia and funguria after oral administration of Candida albicans. Lancet 1969; 1: 598-9.
13. Samonis G, Anaissie EJ, Rosenbaum B, Bodey GP. A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice. Infect Immun 1990; 58: 1514-7.
14. Samonis G, Gikas A, Anaissie EJ et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37: 51-3.
15. Freireich E, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 23: 265-73.
16. Samonis G, Maraki S, Leventakos K et al. Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans. Med Mycol 2006; 44: 233-5.
17. Samonis G, Anaissie EJ, Bodey GP. Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice. Antimicrob Agents Chemother 1990; 34: 2420-2.
18. Pletz MW, Rau M, Bulitta J et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-72.
19. Samonis G, Thomakos N, Liakakos T et al. Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans. Chemotherapy 2001; 47: 350-3.
20. Bergan T, Nord CE, Thorteinsson SB. Effect of meropenem on the intestinal microflora. Eur J Microbiol Infect Dis 1991; 10: 524-7.
21. Chambers HF. Others β-lactam antibiotics. In: Mandell GL, Bennett JE, Dolin R (eds), Principles and Practice of Infectious Diseases, 6th edn. New York: Churchill Livingstone, 2005: 311-8.
22. Alvarez-Lerma F, Grau S, Ferrandez O. Characteristics of doripenem: a new broad spectrum antibiotic. Drug Des Devel Ther 2009; 3: 173-90.
23. Buckley MM, Brogden RN, Barradell LB, Goa KL. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992; 44: 408-44.
24. Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 1989; 24(Suppl. A): 265-77.
25. Wong BK, Sahly Y, Mistry G et al. Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica 2004; 34: 379-89.
26. Mazzei T. The pharmacokinetics and pharmacodynamics of the carbapenems: focus on doripenem. J Chemother 2010; 22: 219-25.
27. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-9.
28. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101-14.